Section: Livestock Bacteria

Tuberculosis in Cattle: Advanced Diagnostics and Eradication Programs

1. Introduction

Bovine tuberculosis (bTB) is a chronic infectious disease of cattle primarily caused by Mycobacterium bovis, a member of the Mycobacterium tuberculosis complex (MTBC). The disease imposes significant economic burdens on the livestock industry through reduced productivity, carcass condemnation at slaughter, trade restrictions, and the costs associated with intensive surveillance and culling programs [1, 2]. The pathogen exhibits a broad host range, infecting both domestic livestock and wildlife reservoirs, which complicates eradication efforts in regions with multi-host systems [3, 4].

The biological basis of M. bovis infection involves inhalation of aerosolized bacilli, alveolar macrophage phagocytosis, and subsequent intracellular survival within phagosomes. The bacterium manipulates host cellular processes, including the induction of oxidative stress via the host protein SH3PXD2B, to evade innate immune clearance [5]. This intracellular niche necessitates cell-mediated immune responses for control, a principle exploited by diagnostic assays measuring interferon-gamma (IFN-gamma) release from sensitized lymphocytes [6].

Effective control of bTB requires a multi-pronged approach: accurate ante-mortem diagnostics, molecular confirmation of suspect lesions, and systematic implementation of test-and-cull eradication programs. This article reviews the advanced diagnostic modalities available for bTB detection, the molecular strategies for differentiating M. bovis from vaccine strains such as M. bovis BCG (Bacille Calmette-Guerin), and the frameworks of national eradication programs that leverage these technologies. The discussion prioritizes veterinary applications and avoids extrapolation to human clinical medicine except where direct comparative host-range parallels are required.

2. Advanced Diagnostic Modalities

2.1. Cell-Mediated Immunity Based Assays

The antemortem diagnosis of bTB relies heavily on the detection of cell-mediated immune responses, as humoral antibody responses are typically weak and inconsistent during the early stages of infection.

Tuberculin Skin Test (TST)

The single intradermal comparative cervical tuberculin (SICCT) test remains the standard screening test for herd-level surveillance. Purified protein derivative (PPD) from M. bovis (bovine PPD) and M. avium (avian PPD) are injected intradermally. The increase in skin-fold thickness at the bovine PPD site is compared to the avian PPD site to differentiate M. bovis infection from sensitization due to environmental nontuberculous mycobacteria (NTM) [6]. Operator variability in injection technique and measurement is a recognized limitation. Refresher training programs for veterinary field technicians significantly improve the consistency and accuracy of TST application and interpretation [7].

Interferon-Gamma Release Assay (IGRA)

The IGRA (e.g., Bovigam assay) measures IFN-gamma release from whole blood leukocytes following stimulation with specific antigens (bovine and avian PPD, or more specific recombinant antigens such as ESAT-6, CFP-10, and Rv2656c [8]). The assay quantifies IFN-gamma concentration using a sandwich ELISA format. IGRA offers several advantages over TST: it requires a single animal handling event (blood collection) and provides results within 24 to 48 hours, and it exhibits higher sensitivity in detecting early or anergic infections. The assay is particularly valuable for testing animals with thick skin that are difficult to measure (e.g., water buffalo) and for confirming inconclusive TST reactors [6].

A key diagnostic challenge is the specificity of both TST and IGRA when cross-reactions occur with NTM. Detection of NTM in milk and nasal swabs from TST-positive and IGRA-positive animals has been documented, underscoring the need for ancillary molecular testing to confirm M. bovis infection [6].

2.2. Molecular Detection and Differentiation

Molecular assays provide definitive confirmation of M. bovis infection from clinical samples (tissues, lymph nodes, swabs, milk) and are essential for differentiating M. bovis from other MTBC members and from NTM. These assays are also critical for distinguishing field strains from M. bovis BCG, a live attenuated vaccine used in some control strategies or encountered in research settings.

Conventional and Real-Time PCR Assays

Conventional PCR targeting the IS6110 insertion element (present in multiple copies in M. tuberculosis but in a single copy or absent in some M. bovis strains) and the RD4 region of difference (which is deleted in M. bovis BCG but present in virulent M. bovis) are standard. TaqMan quantitative real-time PCR (qRT-PCR) assays offer higher throughput, quantification of bacterial burden, and reduced risk of amplicon contamination. A TaqMan qRT-PCR assay targeting specific genetic loci has been validated for detecting Mycobacterium orygis (a member of the MTBC) in lung tissues and lymph nodes, demonstrating the adaptability of these methods for different MTBC members [9].

Novel PCR-Based Platforms

The PCR(BIO/DIG)-ELISA assay represents a hybrid approach. PCR amplification is performed using biotinylated or digoxigenin-labeled primers, followed by a colorimetric ELISA-based detection of the amplicons. This method provides sensitivity comparable to real-time PCR without the requirement for expensive fluorogenic probes and specialized thermocyclers, making it a potentially cost-effective strategy for improving diagnostic efficacy in resource-limited settings [10].

2.3. Post-Mortem and Serological Assays

Post-Mortem Inspection and Lesion Detection

Systematic post-mortem inspection at slaughterhouses remains a cornerstone of bTB surveillance. Typical lesions include caseous granulomas in the retropharyngeal, bronchial, and mediastinal lymph nodes, as well as in lung parenchyma. However, lesion detection sensitivity is operator-dependent, and small or atypical lesions may be missed. The economic impact of bTB-like lesions at slaughter, including carcass condemnation and downgrading, has been evaluated in epidemiological surveys [1]. Furthermore, slaughterhouse data provide valuable information on prevalence and spatial distribution of infection [11].

Serological Assays

While historically considered inferior to CMI tests, modern serological assays (such as the MycoPac dual lateral flow assay and quantum dot microsphere immunochromatographic assays [12]) have improved diagnostic performance, particularly for detecting TB in advanced stages of disease or in animals exhibiting anergic responses. These assays are most valuable when used in parallel with CMI tests to maximize overall diagnostic sensitivity.

The following table summarizes the target analyte, sample type, diagnostic phase, and primary advantages of key diagnostic assays.

| Assay Type | Target Analyte | Sample Type | Diagnostic Phase | Primary Advantages | | :-, | :-, | :-, | :-, | :-, | | Single Intradermal Comparative Cervical Tuberculin (SICCT) Test | Cell-mediated immunity (delayed-type hypersensitivity) | In vivo (skin) | Antemortem, herd screening | Low cost, established framework, no laboratory required | | Interferon-Gamma Release Assay (IGRA) | IFN-gamma released from sensitized lymphocytes | Whole blood (heparinized) | Antemortem, confirmatory | High sensitivity, single visit, rapid results (24-48 h) | | Conventional and Real-Time PCR (qRT-PCR) | M. bovis DNA (e.g., IS6110, RD4) | Tissues, lymph nodes, milk, swabs | Confirmatory, post-mortem | High specificity, species differentiation, BCG discrimination | | PCR(BIO/DIG)-ELISA | M. bovis DNA amplicons | Tissues, lymph nodes | Confirmatory | High sensitivity, lower equipment cost than qRT-PCR | | Lateral Flow Assay / Immunochromatographic Assay | M. bovis antibodies | Serum, milk | Antemortem, serological | Rapid (15-20 min), pen-side testing, simple to perform | | Post-Mortem Inspection | Gross pathological lesions | Carcass, organs | Post-mortem, surveillance | Low cost, routine slaughterhouse application |

3. Differentiation of M. bovis Field Strains from M. bovis BCG

The use of M. bovis BCG as a vaccine in cattle, while not widespread globally, presents a critical diagnostic challenge. Vaccinated animals can develop positive immune responses on TST and IGRA, leading to false-positive interpretations within eradication programs. Molecular differentiation is therefore indispensable.

The M. bovis BCG genome is characterized by several regions of difference (RD) that are deleted relative to virulent M. bovis. The RD1 region, which encodes the potent antigens ESAT-6 and CFP-10, is absent in all BCG substrains. Therefore, IGRA using recombinant ESAT-6 and CFP-10 antigens (instead of PPD) provides a means of DIVA (Differentiating Infected from Vaccinated Animals).

At the DNA level, PCR assays targeting the RD1 deletion or specific single nucleotide polymorphisms (SNPs) can differentiate field M. bovis from BCG directly from tissue samples. The PCR(BIO/DIG)-ELISA assay, for instance, can be designed to amplify sequences within RD1 or other M. bovis-specific genomic targets, providing a colorimetric readout that distinguishes wild-type infection from BCG vaccination [10]. This molecular confirmation is essential for maintaining the integrity of eradication programs in areas where BCG is deployed.

4. Eradication Program Strategies

National bTB eradication programs typically follow a structured framework based on stringent diagnostic testing, removal of test-positive animals, movement restrictions, and continuous surveillance.

4.1. Core Components of Eradication Programs

  1. Herd-Level Surveillance: Regular testing of herds using the SICCT test. The testing frequency (e.g., annual, biennial) depends on the prevalence and historical status of a region.
  2. Confirmatory Testing: Inconclusive or positive reactors on TST are subjected to supplementary testing, typically the IGRA, to increase specificity before culling decisions are made.
  3. Slaughter Surveillance: Mandatory post-mortem inspection at abattoirs to detect gross lesions of TB. All suspect lesions are submitted for histopathology and molecular confirmation [1, 11].
  4. Trace-Back and Contact Herd Testing: When an infected animal is identified, the source herd (trace-back) and herds that received potentially infected animals (trace-forward) are identified and tested to break transmission chains.
  5. Movement Restrictions: Infected or suspect herds are placed under movement restrictions to prevent the spread of infection to uninfected herds.
  6. Epidemiological Investigation: Investigations aimed at identifying risk factors (e.g., wildlife reservoirs, shared pastures) that contribute to herd breakdowns [2]. Network approaches incorporating pathogen shedding data can identify super-spreader hosts in multi-host systems [3].

4.2. The Role of Wildlife Reservoirs

The persistence of bTB in domestic cattle is often linked to infection in sympatric wildlife species, such as the European badger (Meles meles) in the UK and Ireland, the brushtail possum (Trichosurus vulpecula) in New Zealand, and wild boar (Sus scrofa) in the Iberian Peninsula. Wildlife management strategies are an integral part of many eradication programs. Fecal microbiome analysis has revealed that social group structure and age influence gut microbial composition in badgers, with potential implications for TB infection dynamics [4]. Shedding-weighted network models, constructed using camera trap data, provide a method to estimate contact rates and pathogen transmission risk across multi-host communities [3].

4.3. Economic and Social Considerations

The economic impact of bTB includes direct costs (testing, culling compensation, surveillance) and indirect costs (trade restrictions, reduced herd value). Systematic reviews and meta-analyses emphasize that prevalence and risk factors vary considerably by region, with herd size, cattle density, and proximity to wildlife being significant predictors of infection [2]. The slaughter of test-positive animals, even with compensation, generates social and economic strain within farming communities.

5. Workflow of a Modern bTB Diagnostic and Eradication Program

The following Mermaid diagram illustrates the decision-making workflow that integrates advanced diagnostics into a national eradication program.

flowchart TD
    A[Routine Herd Screening], > B{SICCT Test Result}
    B, >|Negative| C[Clear Herd Status]
    B, >|Inconclusive| D[IGRA Confirmatory Test]
    B, >|Positive| D

    D, > E{IGRA Result}
    E, >|Negative| F[Repeat SICCT in 60 days]
    F, > B
    E, >|Positive| G[Animal Culled]

    G, > H[Post-Mortem Inspection]
    H, > I{Gross Lesions Present?}
    I, >|Yes| J[Lesion Sampling]
    I, >|No| K[Routine Tissue Sampling]

    J, > L[PCR / qRT-PCR for M. bovis IS6110 & RD4]
    K, > L

    L, > M{Result: M. bovis Field Strain?}
    M, >|Yes (RD4+) | N[Confirmed bTB Case]
    M, >|No (RD4-) | O[NTM or BCG Differentiation Required]

    O, > P[RD1 / ESAT-6/CFP-10 PCR]
    P, > Q{BCG Confirmed?}
    Q, >|Yes| R[Exclude from bTB Statistic]
    Q, >|No| S[Confirm NTM / Other MTBC]

    N, > T[Tracing: Source & Contact Herds]
    T, > U[Epidemiological Investigation]
    U, > V[Wildlife Risk Assessment?]
    V, >|Yes| W[Network & Camera Trap Analysis]
    W, > X[Targeted Wildlife Control]
    V, >|No| Y[Enhanced Biosecurity]

    X & Y, > Z[Repeat Herd Testing]
    Z, > A

6. Conclusion

Advanced diagnostics have transformed the landscape of bovine tuberculosis control. The integration of IGRA with molecular confirmation via qRT-PCR and PCR-ELISA platforms provides a high-performance diagnostic cascade that maximizes both sensitivity and specificity. Molecular differentiation of field M. bovis strains from M. bovis BCG is essential for the integrity of vaccination-based control strategies. Successful eradication programs must combine these diagnostic tools with robust epidemiological frameworks that address multi-host transmission dynamics and wildlife reservoirs. Continued investment in assay development and implementation science will be critical for reducing the global burden of this economically and ecologically significant livestock disease.

References

[1] Balla EH, Besseboua O, Dergal NB, et al. Epidemiological Survey and Economic Impact of Ruminant Tuberculosis-like Lesions at Slaughterhouses in Two Areas of Northern Algeria (2019-2024): A One Health Assessment. Pathogens. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42198672/

[2] Wang Q, Wang XN, Liu XQ, et al. Prevalence and risk factors of bovine tuberculosis in dairy cattle, 2020-2025: A systematic review and meta-analysis of available literature. Prev Vet Med. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42176585/

[3] Barroso P, Silk MJ, Perelló A, et al. Shedding-weighted network approaches for understanding tuberculosis maintenance in multihost systems using camera traps. Ecol Appl. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42244255/

[4] Meadows NML, Delahay RJ, McDonald RA, et al. Fecal Microbiome Varies With Social Group, Age and Bovine Tuberculosis Infection in the European Badger (Meles meles). Mol Ecol. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42175702/

[5] Liu D, Zhang T, Xu Z, et al. Mycobacterium bovis induces cellular oxidative stress via the host protein SH3PXD2B. BMC Vet Res. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42231287/

[6] Pal S, Samanta S, Haque MZ, et al. Detection of nontuberculous mycobacteria in milk and nasal swab of cattle tested positive by tuberculin skin test, Interferon-γ release assay and MycoPac dual lateral flow assay. Antonie Van Leeuwenhoek. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42189300/

[7] Rikhotso BO, Pretorius O, Thompson PN, et al. Benefits of a tuberculin skin testing refresher training programme for veterinary field technicians in the Bushbuckridge Municipality, South Africa. J S Afr Vet Assoc. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42153752/

[8] Du Y, He P, Dang W, et al. Rv2656c: A Potential Candidate Antigen Associated with Latent Tuberculosis Infection. Vaccines (Basel). 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42188812/

[9] Prajapati SK, Narang D, Chandra M, et al. Molecular detection of Mycobacterium orygis in lung tissues and lymph nodes using conventional and TaqMan qRT-PCR Assay. Vet J. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42250599/

[10] Fabiano SN, Cislaghi AP, Canal AM, et al. Strategy for Improving the Diagnostic Efficacy of Bovine Tuberculosis Using a Novel PCR(BIO/DIG)-ELISA Assay. Vet Res Commun. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42171851/

[11] Njoga EO, Kperegbeyi JI, Onwumere-Idolor OS, et al. Animal Welfare, Carcass-Processing Practices and Post-Mortem Lesions in Nigerian Municipal Slaughterhouses: Implications for Meat Quality and Public Health Security. Vet Sci. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42188909/

[12] Chen M, Yan X, Zhao J, et al. Detection of Bovine Brucellosis Antibodies in Serum and Milk Using Quantum Dot Microspheres Immunochromatographic Assay. Microorganisms. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42197446/

[13] Ansabayeva L, Nurgaliyev B, Darmenova A, et al. Veterinary-sanitary evaluation and biochemical quality of beef from cattle with chronic infectious diseases: Impact of chronic brucellosis on nutritional composition. Vet World. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42245466/

[14] Islam F, Rahman S, Karim MS, et al. Steroid-Responsive Bradycardia in a Patient with Presumptive Isolated Intestinal Tuberculosis: A Case Report. Clin Med Insights Case Rep. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42238550/

[15] Kuhn C, Radon K, Pérez Morales FM, et al. Human-animal contact and zoonotic exposure from wild and domestic animals: A cross-sectional study in wildlife-rich areas of Bolivia, Chile, and Guatemala. One Health. 2026. URL: https://pubmed.ncbi.nlm.nih.gov/42183050/